EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER
Liver Cancer Summit 20223-4 February 2022
N. Poster
Poster title
Applicant name
Status
 |
|
|
|
| PO-004 | Texture analysis using computed tomography data may be helpful for the risk stratification of clinical significant portal hypertension in patients with liver cirrhosis | Shang Wan |  Received |
 |
|||
| PO-005 | Quantitative parameters of esophageal varices based on computed tomography may be used for predicting severe varices in patients with liver cirrhosis | Shang Wan | Received |
|
|||
| PH-017 | Mixed HCC-CCA originates from hepatic progenitor cells, is dependent on IL6 signaling and is ablated by senolytic agents | nofar rosenberg | Received |
|
|||
| PO-022 | Hepatocellular carcinoma is associated with an increased prevalence of metabolic syndrome after liver transplantation | Asahi Hoque | Received |
|
|||
| PO-024 | Occult hepatitis B virus infection and hepatocellular carcinoma occurrence after hepatitis C virus eradication: the silent enemy | Cristina Muzica | Received |
|
|||
| PH-025 | A new 3D Slicer plug-in for the interactive annotation and segmentation of liver anatomy | Antoine Vacavant | Received |
|
|||
| PO-028 | Mathematical modeling of cancer cells and vasculature dynamics with serological and imaging biomarkers suggests synergistic effects of TACE and TKIs in HCC patients | Francesco Damone | Received |
|
|||
| PH-029 | Independent validation of a glycomics-based test associated with risk of HCC development in cirrhosis: a new tool for screening optimisation? | Verhelst Xavier | Received |
|
|||
| PH-030 | Pretransplant changes in serum protein glycosylation are associated to risk of HCC recurrence after liver transplantation and provide a potential prognostic biomarker: a proof-of-concept study | Verhelst Xavier | Received |
|
|||
| PH-038 | Circulating tumor DNA methylation markers for diagnosis of liver cancer: A multicenter diagnostic trial | Maomao Cao | Received |
|
|||
| PO-047 | The clinical experience with stereotactic ablative radiotherapy for hepatocellular carcinoma in a tertiary referral center: a case series | Sjoerd Spijkerboer | Received |
|
|||
| PH-058 | The systemic inflammatory response identifies patients with adverse clinical outcome from immunotherapy in hepatocellular carcinoma. | Claudia Fulgenzi | Received |
|
|||
| PO-064 | Gut bacteria modulate anti-tumour immunity in patients with Hepatocellular Carcinoma | Dhruti Devshi | Received |
|
|||
| PO-068 | Hepatocellular carcinoma alters granulopoiesis to produce neutrophils with an immature phenotype | Daniel Geh | Received |
|
|||
| PH-073 | Tumor intrinsic and extrinsic role of Axl in models of hepatocellular carcinoma | Kristina Breitenecker | Received |
|
|||
| PH-076 | Transarterial chemoembolization for hepatocellular carcinoma in clinical practice: temporal trends and survival outcomes over the last three decades in Italy | Filippo Pelizzaro | Received |
|
|||
| BP-094 | PRAME is a novel target of Axl signaling in hepatocellular carcinoma progression | Viola Hedrich | Received |
|
|||
| PH-098 | Effect of liver stiffness on hepatocellular carcinoma phenotype in a biomimetic 3D model | Jaafar Khaled | Received |
|
|||
| PO-102 | Inhibiting IRE1-a endonuclease activity potentiates the effect of doxorubicin in hepatocellular carcinoma. | MARIA KOPSIDA | Received |
|
|||
| PO-107 | Ouctome of hydrodissection radiofrequency ablation in patients with pericholecystic hepatocellular carcinoma | Benedetta Stefanini | Received |
|
|||
| PO-119 | Efficacy of combination therapy with lenvatinib, programmed cell death 1 inhibitors and transarterial therapy: a propensity score-matching cohort study | Wei Lu | Received |
|
|||
| BP-120 | Hepatocellular carcinoma tumor burden in the GAN diet-induced obese mouse model of NASH with advanced fibrosis | Michael Feigh | Received |
|
|||
| BP-122 | Unrecognized liver cirrhosis: common and associated with worse survival in patients diagnosed with hepatocellular carcinoma a Swedish nationwide cohort study | Juan Vaz | Received |
|
|||
| PO-126 | Novel platinum-based chemotherapeutic agents halt cholangiocarcinoma progression through the induction of inter-strand DNA breaks, preventing DNA repair mechanisms | Irene Olaizola | Received |
|
|||
| PH-127 | Fatty acid oxidation fuels the progression of highly proliferative cholangiocarcinoma cells | Mikel Ruiz de Gauna | Received |
|
|||
| PH-128 | Progression patterns and therapeutic sequencing following immune checkpoint inhibition for HCC: an observational study. | David J Pinato | Received |
|
|||
| PO-129 | Clinicopathological and survival features of hepatic lymphomas: a retrospective single-center study | Emanuel Dias | Received |
|
|||
| PO-132 | Enhanced recovery after surgery: application of 2016 liver surgery guidelines in a middle volume western center | Alessandro Fogliati | Received |
|
|||
| PO-135 | Prominent pseudoacini in focal nodular hyperplasia: a potential diagnostic pitfall | Donghai Wang | Received |
|
|||
| PO-141 | Investigating CXCR2 inhibition anti-PD1 immunotherapy in a NASH-HCC mouse model using Imaging Mass Cytometry | Erik Ramon Gil | Received |
|
|||
| PO-143 | Hepatocellular carcinoma recurrence post Liver transplant | Yaqza Hussain | Received |
|
|||
| PO-148 | Systemic treatments with tyrosine kinase inhibitors and platinum-based chemotherapy in patients with unresectable or metastatic hepato-cholangiocarcinoma | Elia Gigante | Received |
|
|||
| PO-150 | Involvement of E2F2-miR34a-5p axis in the metabolic dysregulation of MAFLD-related HCC | Maider Apodaka Biguri | Received |
|
|||
| PO-154 | Association between metabolic disorders and biliary tract cancer: impact of an emergent risk factor in a real-world cohort. | Leonardo da Fonseca | Received |
|
|||
| PO-159 | Epidemiology of hepatocellular carcinoma in Portugal | Mario Jorge Silva | Received |
|
|||
| PO-160 | CXCR2 inhibition sensitises to anti-PD1 therapy in NASH-HCC | jack leslie | Received |
|
|||
| PH-161 | Opposite roles for PD-1 expressing tissue resident and exhausted T cells in Hepatocellular Carcinoma | Maryam Barsch | Received |
|
|||
| PO-163 | The NADPH oxidase NOX4 regulates redox and metabolic homeostasis in hepatocellular carcinoma | Irene Peñuelas | Received |
|
|||
| PO-170 | P53 and VEGF immunoexpression are predictive biomarkers of Sorafenib efficacy in an experimental model of NASH-related HCC | João Pedro Nassar Reis | Received |
|
|||
| PO-175 | A retrospective real-world study of transarterial gemcitabine-based chemoembolization plus lenvatinib with or without a PD-1 inhibitor for unresectable intrahepatic cholangiocarcinoma | ya li | Received |
|
|||
| PO-176 | Factors associated with the radiological response of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma | Yuka Hayakawa | Received |
|
|||
| PH-177 | Cholangiocarcinoma-on-chip: a 3D liver tumor model | michela polidoro | Received |
|
|||
| PO-179 | Altered glutamine metabolism in intrahepatic cholangiocarcinoma: biological effects of glutaminase inhibitor | michela polidoro | Received |
|
|||
| PH-181 | The development of ex vivo human models of hepatocellular carcinoma in precision cut liver slices for high throughput screening of anti-cancer therapies | Amy Collins | Received |
|
|||
| PO-190 | Role of ABC drug efflux pumps in the resistance of hepatoblastoma to conventional chemotherapy | Candela Cives-Losada | Received |
|
|||
| PO-193 | MiR-30e-3p plays a dual role in hepatocellular carcinoma and predicts sorafenib resistance | Ilaria Leoni | Received |
|
|||
| PH-195 | Usefulness of serum metabolomic profiling for the differential diagnosis in liver cancer: a validation study | Rocio IR Macias | Received |
|
|||
| PO-202 | Direct and indirect antitumoral effects of cold atmospheric plasma : a disruptive technological approach for the local treatment of cholangiocarcinoma | Allan Pavy | Received |
|
|||
| PO-203 | The probability to be cured after surgery for hepatocellular carcinoma: can these patients reach again the general population life span? A national multicentric epidemiologic study | Simone Famularo | Received |
|
|||
| PO-211 | Stratification of cirrhosis etiologies identifies novel immune biomarkers for early stage hepatocellular carcinoma | Boris Beudeker | Received |
|
|||
| PO-221 | Liver biopsy biomarkers in a phase 1 study of the prodrug MIV-818 demonstrates proof-of-concept for cancer in the liver | Fredrik Oberg | Received |
|
|||
| PO-224 | Notch signalling is significantly altered in KPPTom mice, a bespoke murine model of intrahepatic cholangiocarcinoma | Anabel Martinez Lyons | Received |
|
|||
| PO-225 | BH3 mimetics for precision prevention for beta-catenin mutant hepatocellular carcinoma | Stephanie May | Received |
|
|||
| PO-231 | Early Kupffer cell depletion does not affect hepatocellular carcinoma progression in mice | Bart Vanderborght | Received |
|
|||
| PO-235 | Disease positioning identifies distinct hepatocellular carcinoma subtypes within genetically engineered mouse models which transcriptionally relate to equivalent subclasses in human hepatocellular carcinoma | Miryam Mller | Received |
|
|||
| PH-241 | ZEB1 expression mediates chemoresistance in cholangiocarcinoma by disrupting the pro/anti-apoptotic balance in stromal myofibroblasts | Javier Vaquero | Received |
|
|||
| PO-259 | Response to sorafenib in HCC is mediated by hypoxia-related proteins and induces distinct immune-related signatures | Jovana Hajduk | Received |
|
|||
| PH-264 | Benefits of tailored HCC surveillance programs on case-fatality rate and cancer-specific mortality using a modelling approach | Massih Ningarhari | Received |
|
|||
| PO-266 | Proteomic profiling for theranostic approches in Hepatocellular Carcinoma | Anne-Aurélie RAYMOND | Received |
|
|||
| PO-267 | Comparative in vitro evaluation of cancer therapies in various hepatocellular carcinoma experimental models | Loraine Cabral | Received |
|
|||
| PO-272 | Senescence-specific adaptive immune response to oncogene-induced-senescence (OIS) within the murine liver | Sarah Gough | Received |
|
|||
| PO-280 | Transcriptomic profiling of primary sclerosing cholangitis associated cholangiocarcinoma identifies novel genes of interest | Megan Illingworth | Received |
|
|||
| PO-284 | Predictors of survival of patients with hepatocellular carcinoma in best supportive care | Claudia Campani | Received |
|
|||
| PO-286 | Characterization of Transforming Growth Factor (TGF)-beta signalling in sorafenib-resistant hepatocarcinoma cell lines. | Ester Gonzalez-Sanchez | Received |
|
|||
| PO-287 | PD1 T-cells correlate with Nerve Fiber Density as a prognostic biomarker in patients with resected perihilar cholangiocarcinoma. | Lara Heij | Received |
|
|||
| PO-288 | Targeting of nuclear receptors and microRNA-21 ameliorates non-alcoholic fatty liver disease progression towards carcinogenesis in mice | André L. Simao | Received |
|
|||
| PH-289 | Lipid droplets are mechanical stresses in non-alcoholic fatty liver disease | Abigail Loneker | Received |
|
|||
| PO-290 | SerpinB3/4 expression is associated with poor prognosis in patients with cholangiocarcinoma | Andrea Martini | Received |
|
|||
| PH-293 | Anticancer activity of novel vicinal diaryl isoxazole compounds in hepatocellular carcinoma | Esra Nalbat | Received |
|
|||
| PH-295 | Serum IL-8 is associated with altered neutrophil phenotype and poorer survival in patients with hepatocellular carcinoma | Helen Louise Reeves | Received |
|
|||
| PO-296 | In vitro effects of magnetic hyperthermia via a nanomodified polymer stent for cholangiocarcinoma treatment | Anjali A. Roth | Received |
|
|||
| PO-300 | Genes modulating liver fat accumulation and lipogenesis predict development of hepatocellular carcinoma among direct antiviral agents treated cirrhotics C with and without viral clearance | Antonio Acquaviva | Received |
|
|||
| PO-302 | Comparison of therapeutic outcomes of liver resection and transarterial chemoembolization in multifocal HCC: a propensity score-matched analysis | Claudia Campani | Received |
|
|||
| PO-306 | Modulation of the cholangiocarcinoma stem-like compartment by monounsaturated fatty acids | Giulia Lori | Received |
|
|||
| PO-307 | Potential role of soluble triggering receptor expressed on myeloid cells 2 in risk stratification of patients with hepatocellular carcinoma | Francesca Baorda | Received |
|
|||
| BP-308 | Liver transplantation for combined hepatocellular-cholangiocarcinoma: An analysis of the European Liver Transplant Registry | Marco Claasen | Received |
|
|||
| PO-309 | Cross-talk between MerTK-expressing stromal cells and cholangiocarcinoma | Mirella Pastore | Received |
|
|||
| PO-312 | Performance of Toronto HCC risk index and aMAP score in predicting HCC development in patient with cirrhosis | Nouha Trad | Received |
|
|||
| PO-313 | Liver transplantation for fibrolamellar hepatocellular carcinoma: An analysis of the European Liver Transplant Registry | Marco Claasen | Received |
|
|||
| PO-314 | Performance of ten non-invasive liver function tests in predicting hepatocellular carcinoma development in patients with cirrhosis | Nouha Trad | Received |
|
|||
Liver Cancer Summit 2022
3-4 February 2022
Search and consult posters online
in an exclusive section
for each poster
in an exclusive section
for each poster
ACTIVE FROM 03/02/2022 TO 03/02/2023
Poster
Gallery
Gallery
Upload
Poster
Poster
Featured Poster
Vote poster
Poster Discussion
Forum
Forum
|
Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress.
|
|
||
|
||||
|
|
